stockrowHims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.
- Revenue
- +38.3%
- EPS
- −294.7%
- Free cash flow
- +5.09%
- Total debt
- +40.8%
Quarter to June 2026, against a year earlier
Follow HIMS
Alert me
Hims & Hers Health, Inc. (HIMS) Piotroski F-score
Hims & Hers Health, Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 6 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | (2.00) |
| FY2024 | 6 | 0.00 |
| FY2023 | 6 | 0.00 |
| FY2022 | 6 | 2.00 |
| FY2021 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 8.97% | 21.94% | Pass | 1 |
| Positive operating cash flow | 300.01m | 251.08m | Pass | 1 |
| Rising return on assets | 8.97% | 21.94% | Fail | 0 |
| Cash flow above net income | 171.64m | 125.05m | Pass | 1 |
| Falling long-term leverage | 0.68 | 0.00 | Fail | 0 |
| Rising current ratio | 1.90 | 1.79 | Pass | 1 |
| No new shares issued | 224,959,000 | 215,939,000 | Fail | 0 |
| Rising gross margin | 73.84% | 79.45% | Fail | 0 |
| Rising asset turnover | 1.64 | 2.57 | Fail | 0 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 8 |
| ALKS Alkermes plc compare | 7 |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 7 |
| LQDA Liquidia Corporation compare | 5 |
| LNTH Lantheus Holdings, Inc. compare | 5 |
| ELAN Elanco Animal Health Incorporated compare | 5 |
| SUPN Indivior Pharmaceuticals Inc. compare | 4 |
| HIMS Hims & Hers Health, Inc. | 4 |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 3 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover
More on HIMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement